Key result
Current lipid-lowering therapy achieved LDL-C <70 mg/dL in 67.5% and <50 mg/dL in 29.9% of Indian patients undergoing coronary revascularization at a median 99 days follow-up.
Why the study?
The study aimed to assess the effectiveness of current lipid-lowering therapy in achieving LDL-C goals in Indian patients undergoing coronary revascularization.
Observational (n=1,275)
Despite contemporary lipid-lowering therapy, a large proportion of Indian patients undergoing coronary revascularization do not achieve strict LDL-C goals, underscoring the need for greater use of combination therapies.
Answers are grounded in this paper and cite their sources.
Current lipid-lowering regimens often miss LDL-C targets post-revascularization; supports intensified therapy but leaves optimal strategies open in Indian cohorts.
This study aimed to assess the effectiveness of current lipid-lowering therapy in achieving low-density lipoprotein cholesterol (LDL-C) goals in Indian patients undergoing coronary revascularization. Consecutive subjects (n = 1275, mean age 60.0 ± 9.7 years, 87.2 % men) with newly diagnosed coronary artery disease and undergoing coronary revascularization during the period 1 Jan 2023 to 31 Dec 2023 were included. After a median follow-up of 99 days (interquartile range 91-109 days), the mean LDL-C was 63.9 ± 24.3 mg/dL with 67.5% and 29.9% of subjects having LDL-C <70 mg/dL and <50 mg/dL, respectively. These proportions were 70.8% and 32.1% for patients treated with high-intensity statin therapy (rosuvastatin 20-40 mg/d or atorvastatin 40-80 mg/d). Among patients treated with rosuvastatin 40 mg/d and ezetimibe 10 mg/d, 53.3% achieved LDL-C <50 mg/dL. These findings underscore the need for greater usage of combination lipid-lowering therapy and agents with high LDL-C lowering efficacy.
No takes yet. Share an insight, caveat, or question.
Bansal et al. (2024) conducted an observational in newly diagnosed coronary artery disease undergoing coronary revascularization (n=1,275). Current lipid-lowering therapy was evaluated on LDL-C <70 mg/dL. Current lipid-lowering therapy achieved LDL-C <70 mg/dL in 67.5% and <50 mg/dL in 29.9% of Indian patients undergoing coronary revascularization at a median 99 days follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: